Evento

Cargando Eventos

« Todos los Eventos

  • Este evento ha pasado.

HOT TOPICS

17 octubre de 09:00 a 14:00

imagen-destacada

HOT TOPICS ASBMR 2020

 

Sábado 17 de Octubre de 2020, Reunión Virtual

 

9:00 – 09:05                Presentación del curso

                                    Dr. José A. Riancho Moral, Dra. Pilar Peris Bernal

 

PRIMER BLOQUE

9:05 – 9:25                  Una visión integrada del microambiente óseo más allá del hueso y cáncer.

Dr. José L. Pérez Castrillón

 

 

9:25 – 9:45                  Optimización del tratamiento secuencial en osteoporosis.

Dra. Nuria Guañabens Gay

 

9:45 – 10:05                Beta bloqueantes: del laboratorio a su aplicabilidad clínica.

Dr. Carlos Gómez Alonso

 

10:05 – 10:15              Discusión

 

SEGUNDO BLOQUE

10:15 – 10:35              Inteligencia artificial en la salud músculo-esquelética.

Dr. Luis Del Rio Barquero

 

10:35 – 10:55              Conceptos vanguardistas: la heterogeneidad celular en la médula ósea.

Dra. Arancha Rodríguez de Gortázar

 

10:55 – 11:15              Aspectos básicos del hueso, aparato digestivo y cerebro.

Dr. Manuel Muñoz Torres

 

11:15 – 11:25              Discusión

11:25 – 11:40             Pausa

TERCER BLOQUE

11:40 – 12:00              Novedades sobre el tratamiento de la osteoporosis a largo plazo y sobre su discontinuación.

Dra. Minerva Rodríguez García

 

12:00 – 12:20              Manejo terapéutico a largo plazo de las fracturas por fragilidad.

Dra. Cristina Carbonell Abella

 

12:20 – 12:40              Nuevas aproximaciones en la terapia de la patología ósea.

Dr. Xavier Nogués Solán

 

12:40 – 12:50              Discusión

 

 

CUARTO BLOQUE

12:50 – 13:10              Nuevas perspectivas: a) historias que inspiran la mecánica ósea en el reino animal; b) modelos de enfermedad con células iPS.

Dr. Manuel Naves Díaz

 

13:10 – 13:30              ¿Es recomendable una estrategia treat-to-target en el abordaje terapéutico de la osteoporosis?

Dr. Guillermo Martínez Díaz-Guerra

 

13:30 – 13:50              Microbioma y hueso.

Dr.Esteban Jodar Gimeno

 

13:50 – 14:00              Discusión y clausura del curso

 

 

 

 

Además de las ponencias y sesiones plenarias que se muestran en el programa, los ponentes comentarán en su presentación varias comunicaciones orales y posters plenarios que se han seleccionado por su interés científico. Este listado de comunicaciones y posters es tentativo y podría variar ligeramente en función del tiempo de exposición del ponente o la no adecuación del mismo para su presentación.

 

Listado Comunicaciones Orales seleccionadas:

Concurrent Orals: Greg Mundy Memorial Session: Bone, Cancer and Metastasis, September 11, 2020, 12:15 PM – Dr. Carlos Gómez Alonso

[1008] Integrin alpha-5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions, September 11, 12:25 PM-12:35 PM

 

Concurrent Orals: Osteocytes/Mechanobiology, September 11, 2020, 12:15 PM – Dra. Arancha Rodríguez de Gortázar

[1013] Control of Osteocytogenesis by a Neuronally−expressed Sp7−dependent Genetic Network September 11, 12:15 PM-12:25 PM

 

Concurrent Orals: Vitamin D and Nutrition, September 11, 2020, 12:15 PM – Dr. José L. Pérez Castrillón

[1019] High-dose Vitamin D Supplementation Affects Bone Density Differently in Females than Males, September 11, 12:15 PM-12:25 PM

[1022] Dairy Supplementation Reduces Fractures and Falls in Institutionalized Older Adults: a Cluster-Randomized Placebo-Controlled Trial, September 11, 12:45 PM-12:55 PM

[1023] Vitamin D Deficiency Is Independently Associated with COVID-19 Severity and Mortality, September 11, 12:55 PM-01:05 PM

 

Concurrent Orals: Bone Marrow Microenvironment and Niches, September 12, 2020, 11:00 AM – Dr. Manuel Naves Díaz

[1025] Sclerostin Depletion May Induce Inflammation in the Bone Marrow, September 12, 11:00 AM-11:10 AM

 

Concurrent Orals: Anabolic and Sequential Osteoporosis Treatment, September 12, 2020, 11:00 AM – Dr.Esteban Jodar Gimeno

[1037] Zoledronic Acid Maintains Areal Bone Density after Denosumab Administration (DATA-HD Extension) September 12, 11:00 AM-11:10 AM

[1038] Effect of Zoledronic Acid on Volumetric Bone Density and Microarchitecture after Denosumab Administration (DATA-HD Extension HR-pQCT Study) September 12, 11:10 AM-11:20 AM

[1041] Kinetic Reconstruction of the Cancellous and Endocortical Remodeling Unit Reveals a Net Positive Bone Balance After 12 Months of Treatment with Romosozumab September 12, 11:40 AM-11:50 AM

[1042] Treatment Sequences With Romosozumab Before or After Antiresorptive Medication September 12, 11:50 AM-12:00 PM

 

Concurrent Orals: Novel Therapies for Rare Bone Disease, September, 12, 2020, 11:00 AM- Dr. Guillermo Martínez Díaz-Guerra

[1044] Efficacy of burosumab in adults with X-linked hypophosphataemia (XLH): A subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 study, September 12, 11:10 AM-11:20 AM

[1045] Three-Year Safety and Efficacy Results of Burosumab for Children Aged 1 to 4 years with X-linked Hypophosphatemia (XLH), September 12, 11:20 AM-11:30 AM

 

 

Concurrent Orals: Issues of Long-term Treatment and Discontinuation, September, 13, 2020, 11:00 AM – Dra. Minerva Rodríguez García

[1061] Bisphosphonate Use and Risk of Atypical Femoral Fractures: A Nationwide Danish Analysis with Blinded Radiographic Review, September 13, 11:10 AM-11:20 AM

[1062] Teriparatide for the healing of incomplete Atypical Femur Fractures: The TAFF Trial, September 13, 11:10 AM-11:20 AM

[1064] Bone matrix quality in traniliac biopsies from post-menopausal wome treated with denosumab for up to 10 years (FREEDOM and FREEDOM extension trials), September 13, 11:30 AM-11:40 AM

[1065] Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial, September 13, 11:40 AM-11:50 AM

[1066] Risk of Incident Atrial Fibrillation with Zoledronic Acid Versus Denosumab: A Propensity-Score Matched Cohort Study, September 13, 11:50 AM-12:00 PM

 

Concurrent Orals: Optimal Osteoporosis Management: Stratified Medicine, Costs and Prevention, September, 13, 2020, 11:00 AM – Dra. Cristina Carbonell Abella

[1067] Effects of the recency of sentinel fractures on conventional estimates of fracture probability using FRAX, September 13, 11:00 AM-11:10 AM

[1068] Surrogate threshold effect: identifying BMD change linked to different levels of fracture risk reduction. Study-level analysis from the FNIH Bone Quality Project, September 13, 11:10 AM-11:20 AM

[1069] Do Women with Lower BMD Benefit More from Anti-fracture Treatment?  An Analysis Pooling Individual Patient Data from 134,000 Women in the FNIH-SABRE RCT Database, September 13, 11:20 AM-11:30 AM

[1070] The associations of peak bone mineral density and rate of bone mineral density loss during the menopause transition and early postmenopause with subsequent fracture: results from the Study of Women’s Health Across the Nation (SWAN), September 13, 11:30 AM-11:40 AM

 

Concurrent Orals: Optimal Osteoporosis Management: Stratified Medicine, Costs and Prevention, September, 13, 2020, 11:00 AM – Dr. Carlos Gómez Alonso

[1071] Osteocalcin, Muscle Function and 15-year Falls Hospitalizations in Older Women: The Perth Longitudinal Study of Ageing Women Study, September 13, 11:40 AM-11:50 AM

 

Concurrent Orals: Energy Metabolism, Bone, Muscle and Fat, September 13, 2020, 11:00 AM – Dr. Manuel Muñoz Torres

[1053] Targeting Ferroptosis Alleviates Type 2 Diabetic Osteoporosis via Suppressing Osteocyte Lipotoxicity, September 13, 11:40 AM-11:50 AM

 

Concurrent Orals: Genomics, Transcriptomics, Proteomics and Metabolomics of Musculoskeletal Disease, September 13, 2020, 11:00 AM – Dr. Xavier Nogués Solán

[1059] Identifying Drug Targets via Whole Exome Sequencing and CRISPR-Cas9, September 13, 11:40 AM-11:50 AM.

 

Concurrent Orals: Bone Interactions with the Immune System, September 14, 2020, 11:00 AM – Dra. Nuria Guañabens Gay

[1076] Blocking of osteocyte Toll-like receptor signaling uncouples bone resorption from inflammation, September 14, 11:30 AM-11:40 AM

[1077] Ovariectomy Induces Bone Loss Via Microbial Dependent Trafficking of Intestinal TNF Producing T Cells and Th17 Cells to the Bone Marrow, September 14, 11:40 AM-11:50 AM

 

 

 

 

 

Concurrent Orals: Diabetes, Obesity and Bone Health, September 14, 2020, 11:00 AM – Dr. Manuel Muñoz Torres (a seleccionar una de entre las siguientes presentaciones):

[1079] Fracture Risk in Type 2 Diabetes: Longitudinal Glycemic Control Based Prediction and the Efficacy of Medications.

[1080] Use of Sodium-glucose Co-transporter-2 Inhibitors, Changes in Body Mass Index and Risk of Fracture in the United Kingdom (UK.

[1081] Greater Serum Carboxy-Methyl-Lysine (CML) is Associated with Increased Fracture Risk in Type 2 Diabetes: The Health, Aging and Body Composition Study.

  1. Dietary Advanced glycation end-products (dAGEs) and bone health: a cross-sectional analysis in Rotterdam study.

[1083] Saturated and Unsaturated Bone Marrow Lipids Have Distinct Effects on Bone Density and Fracture Risk in Older Adults.

[1084] Role of the Gut Microbiome in Bone Metabolism in Severe Obesity and After Sleeve Gastrectomy.

 

Concurrent Orals: Musculoskeletal Development and Progenitor Lineage Determination, September 14, 2020, 11:00 AM – Dr. Manuel Naves Díaz

[1085] The Stem Cell Basis of Bifurcation between Adipogenic versus Osteogenic Lineages, September 14, 11:00 AM-11:10 AM

 

Concurrent Orals: Rare Bone Diseases: Translational, September 15, 2020, 11:00 AM – Dr. Xavier Nogués Solán

[1112] Evaluation of Epigenetic Regulation of Osteogenesis Imperfecta Severity with Circulating microRNAs: the miROI Study, September 15, 11:30 AM-11:40 AM

 

Concurrent Orals: Bone Biomechanics and Responses to Mechanical Stimulation, September 15, 2020, 11:00 AM – Dr. Luis del Río Barquero

[1099] Small changes in structure and mineral density after exercise can have profound effects on mechanical strength, September 15, 11:20 AM-11:30 AM

 

Concurrent Orals: Skeletal Consequences of Diverse Morbidities, September 15, 2020, 11:00 AM – Dra. Nuria Guañabens Gay

[1115] The Effect of Low-dose Oral Glucocorticoid Therapy on Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis: the UK Clinical Practice Research Datalink, September 15, 11:00 AM-11:10 AM

[1120] Long bone fractures in fibrous dysplasia/McCune-Albright Syndrome: prevalence, natural history, and risk factors, September 15, 11:50 AM-12:00 PM

 

 

 

Listado Posters Plenarios seleccionadas:

[P-043] One Year of Denosumab after Two Years of Teriparatide in Premenopausal Idiopathic Osteoporosis (IOP): Changes in Skeletal Indices using High Resolution Peripheral Computed Tomography (HR-pQCT) – Dr. Guillermo Martínez Díaz-Guerra

[P-159] Non-bone metastatic cancers promote osteocytic bone destruction – Dr. Manuel Naves Díaz

[P-464] PPARG in Osteocytes Regulates Sclerostin Expression, Bone Mass and Marrow Adiposity – Dra. Arancha Rodríguez de Gortázar

[P-486] Assessment of machine-learning technologies for predicting major osteoporotic fracture in 25,772 postmenopausal women with genomic and phenotypic data – Dr. Luis del Río Barquero

[P-487] Comparison of Short-Term and 10-year Probabilities to Characterise Fracture Risk After a Recent Sentinel Fracture – Dr. Carlos Gómez Alonso

[P-490] Automated Workflow for Vertebral Deformity Measurements on CT and MRI Scans Using Artificial Intelligence – Dr. Luis del Río Barquero

[P-538] Treat-to-Target in Osteoporosis: Total Hip BMD T-Score as an Indicator of Fracture Risk in Bisphosphonate-Treated Postmenopausal Women from Real‏ World Data – Dr. Carlos Gómez Alonso

[P-576] Calcifediol Soft Gelatin Capsules Have a Superior Efficacy and a More Rapid Response than Cholecalciferol for the Management of Vitamin D Deficiency in Postmenopausal Women: Calcifediol Must be Considered in Therapeutic Guidelines – Dr. José L. Pérez Castrillón

[P-599] Identification of a new circulating cellular biomarker from patients with postmenopausal osteoporosis – Dra. Arancha Rodríguez de Gortázar

[P-637] Infection among Denosumab and Alendronate Users for Osteoporosis – Dr. Manuel Muñoz Torres

[P-638] Factors associated with vertebral fractures after Denosumab. A retrospective study of 797 cases – Dr. Xavier Nogués Solán

[P-640] Cardiovascular Risk in Patients Treated with Romosozumab: Disproportional Meta-Analysis – Dr. Manuel Muñoz Torres

[P-642] Romosozumab After Denosumab Improves Lumbar Spine and Maintains Total Hip Bone Mineral Density in Postmenopausal Women with Low Bone Mass – Dra. Minerva Rodríguez García

[P-646] Estimating Relative Fracture Reduction of Romosozumab versus Teriparatide for Postmenopausal Osteoporosis Using Bone Mineral Density Outcomes – Dr. Xavier Nogués Solán

[P-647] Sequential Therapy with Denosumab After Teriparatide Leads to Large Increases in Spine and Hip BMD in Premenopausal Women with Idiopathic Osteoporosis (IOP) – Dr. Guillermo Martínez Díaz-Guerra

[P-756] Real-world evidence of the progressive and cumulative morbidity arising from X-linked hypophosphatemia (XLH) over the adult life course – Dr. Guillermo Martínez Díaz-Guerra

[P-761] Lesional Sodium Fluoride uptake decreases on PET-CT scan in patients with Fibrous Dysplasia/McCune Albright syndrome treated with Denosumab – Dr. Luis del Río Barquero

Detalles

Fecha:
17 octubre
Hora:
09:00 a 14:00
Web:
https://www.asbmr.org/Default.aspx

Organizador

SEIOMM
Teléfono:
666 666 666
Correo electrónico:
congreso@seiomm.org
Web:
www.seiomm.org
Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen
Gebro